{"id":15159,"date":"2022-01-11T11:32:58","date_gmt":"2022-01-11T10:32:58","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=15159"},"modified":"2022-03-11T11:35:56","modified_gmt":"2022-03-11T10:35:56","slug":"dupilumab-en-pacientes-con-dermatitis-atopica","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/dupilumab-en-pacientes-con-dermatitis-atopica\/","title":{"rendered":"Dupilumab en pacientes con Dermatitis At\u00f3pica"},"content":{"rendered":"<p>Dupilumab es eficaz en el tratamiento de pacientes adultos con dermatitis at\u00f3pica de moderada a grave, reduciendo r\u00e1pidamente los signos y s\u00edntomas y mejorando el impacto psicol\u00f3gico y la calidad de vida, seg\u00fan se desprende de los resultados del estudio <em><strong>\u201cPatient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results\u201d<\/strong><\/em><\/p>\n<p>El art\u00edculo publicado en la revista Life, de los autores Marron SE, Tomas-Aragones L, Moncin-Torres CA, Gomez-Barrera M, Garcia-Latasa de Aranibar FJ, presenta entre sus conclusiones que la percepci\u00f3n de satisfacci\u00f3n mostr\u00f3 que los pacientes valoraban significativamente el tratamiento con dupilumab mejor que los tratamientos anteriores.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dupilumab es eficaz en el tratamiento de pacientes adultos con dermatitis at\u00f3pica de moderada a grave, reduciendo r\u00e1pidamente los signos y s\u00edntomas y mejorando el impacto psicol\u00f3gico y la calidad de vida, seg\u00fan se desprende de los resultados del estudio \u201cPatient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results\u201d El art\u00edculo&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/dupilumab-en-pacientes-con-dermatitis-atopica\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":15160,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-15159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15159"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=15159"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15159\/revisions"}],"predecessor-version":[{"id":15161,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15159\/revisions\/15161"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/15160"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=15159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=15159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=15159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}